
Work Here?
IDEX manufactures high-precision components and systems for specialized industries, including medical diagnostics, fire safety, and industrial manufacturing. Its products, such as liquid subassemblies for labs and pumps for fire trucks, work by providing exact control and measurement in environments where accuracy is critical to safety or research. Unlike competitors that focus on mass-market goods, IDEX specializes in niche markets by engineering custom solutions for highly technical problems. The company's goal is to provide reliable, engineered tools that help professionals in health, rescue, and industry perform essential tasks more effectively.
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Northbrook, Illinois
Founded
1987
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$531.2M
Above
Industry Average
Funded Over
2 Rounds
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
SilverEdge cooperative. Is IDEX Corporation stock outperforming the S&P 500? Neha Panjwani Barchart 51 minutes ago Northbrook, Illinois-based IDEX Corporation (IEX) offers applied solutions globally. Valued at $16.4 billion by market cap, the company has a diverse portfolio of over 50 businesses, offering products like industrial pumps, lubrication systems, banding and clamping devices, and rescue tools. Companies worth $10 billion or more are generally described as "large-cap stocks," and IEX perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the specialty industrial machinery industry. IEX derives its edge from manufacturing high-margin, mission-critical equipment with strong switching costs. Its disciplined 80/20 operating model optimizes profitability, while steady cash flows fund bolt-on acquisitions across resilient end-markets like life sciences and fire safety. Despite its notable strength, IEX slipped 8.7% from its 52-week high of $243.80, achieved on Jul. 29. Over the past three months, IEX stock declined 1.1%, underperforming the S&P 500 Index's ($SPX) 3.5% gains during the same time frame. In the longer term, shares of IEX rose 25.1% on a YTD basis and climbed 38.2% over the past 52 weeks, outperforming SPX's YTD gains of 13.4% and 16.5% returns over the last year. To confirm the bullish trend, IEX has been trading above its 200-day moving average since early December, 2025. However, the stock is trading below its 50-day moving average since early September. IEX outperformed on robust demand in data center, semiconductor, and space & defense, with HST leading as organic orders jumped 28% overall and 47% in HST, boosting backlog and visibility. Volume leverage, 8020 execution, and a one-time tariff refund tailwind drove margin expansion. Management is raising capex for capacity and remains focused on bolt-on M&A to sustain growth. On Jul. 29, IEX shares closed up more than 2% after reporting its Q2 results. Its adjusted EPS of $2.32 exceeded Wall Street expectations of $2.10. The company's revenue was $920.6 million, surpassing Wall Street forecasts of $902.4 million. The company expects full-year adjusted EPS in the range of $8.70 to $8.85. IEX's rival, Nordson Corporation (NDSN) has taken the lead over the stock, with a 30.7% uptick on a YTD basis and 39.7% gains over the past 52 weeks. Wall Street analysts are reasonably bullish on IEX's prospects. The stock has a consensus "Moderate Buy" rating from the 14 analysts covering it, and the mean price target of $259.14 suggests a potential upside of 16.5% from current price levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
IDEX Corporation has amended its revolving credit facility, extending the maturity date to September 3, 2031, from the previous November 1, 2027. The facility maintains its $800 million principal amount. The agreement, finalised on September 3, 2026, allows for up to $100 million in letters of credit and $50 million in same-day swingline loans. IDEX may request additional lending commitments, capped at a $400 million increase. Bank of America serves as administrative agent, with JPMorgan Chase Bank, PNC Bank, and Wells Fargo Bank as co-syndication agents. The proceeds will fund working capital and general corporate purposes, including refinancing existing debt. The agreement includes standard covenants for senior unsecured credit facilities, featuring a quarterly-tested leverage ratio and restrictions on liens and mergers. Voluntary prepayments are permitted without penalty.
IDEX reported Q2 revenues of $920.6 million, up 6.4% year-on-year and exceeding analyst expectations by 1.7%. The company delivered a strong quarter with full-year EPS guidance surpassing forecasts and beating EBITDA estimates. IDEX achieved the highest guidance raise among gas and liquid handling stocks tracked. The stock rose 4.3% following the earnings announcement and currently trades at $234.37. The gas and liquid handling sector showed strength overall in Q2, with 11 tracked companies beating revenue consensus estimates by 2.1% on average. However, next quarter's guidance came in 0.8% below expectations. SPX Technologies led the group with revenues of $679 million, up 22.9% year-on-year, outperforming expectations by 5.8%. The stock gained 4.2% after reporting.
IDEX Corporation reported strong second quarter 2026 results, exceeding expectations with organic sales growth of 5% and adjusted earnings per share of $2.32, up 12% year-over-year. Adjusted EBITDA margin expanded 70 basis points to 28.1%. The company's performance was driven by higher volumes from growth platforms and strong operational execution. Results were modestly impacted by IEEPA tariff refunds, which slightly reduced organic growth whilst providing minor favourability to margins and earnings. President and Chief Executive Officer Eric Ashleman noted the results continued momentum established earlier in the year. The earnings call featured remarks from Ashleman and Chief Financial Officer Sean Gillen, who provided additional financial details and an updated outlook for 2026.
Idex reported Q2 2026 revenue of $920.6 million, up 6.4% year-over-year, beating the consensus estimate of $902.43 million by 2.01%. EPS came in at $2.32, compared to $2.07 in the prior-year quarter, exceeding the $2.10 estimate by 10.48%. The Health & Science Technologies segment led growth with $415 million in revenue, up 13.6% year-over-year and above the $406.67 million estimate. Fluid & Metering Technologies generated $317.1 million, whilst Fire & Safety/Diversified Products posted $189.9 million. Organic sales growth reached 5%, surpassing the 3.4% analyst estimate. Idex shares have declined 1% over the past month, compared to a 1.9% gain for the S&P 500.
Find jobs on Simplify and start your career today
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Northbrook, Illinois
Founded
1987
Find jobs on Simplify and start your career today